| 2018 | 2019 | 2020 | 2021 (projected) | Revenues USD | 3.25 M | 5.53 M | 6.36 M | 6.86 M | Revenues | 3.25 M | 5.53 M | 6.36 M | 6.86 M |
Will Biocept (NASDAQ:BIOC) current volatility spike continue?
 | By Vlad Skutelnik | Macroaxis Story |
40% of stocks are less volatile than Biocept, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. As many adventurous traders are excited about healthcare space, it is only fair to go over the risk of shorting Biocept based on its current volatility spike. We will go over a few points Biocept investors should remember regarding its volatility.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
The company conducts business under Healthcare sector and is part of Diagnostics & Research industry. Volatility is a rate at which the price of Biocept or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Biocept may increase or decrease. In other words, similar to Biocept's beta indicator, it measures the risk of Biocept and helps estimate the fluctuations that may happen in a short period of time. So if prices of Biocept fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.
Watch out for price decline
Please consider monitoring Biocept on a daily basis if you are holding a position in it. Biocept is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Biocept stock to be traded above the $1 level to remain listed. If Biocept stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Biocept's Liquidity
Biocept financial leverage refers to using borrowed capital as a funding source to finance Biocept ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biocept financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Biocept's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Biocept's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Biocept's total debt and its cash.
A Deeper look at Biocept
Biocept reported the previous year's revenue of 10.73 M. Net Loss for the year was (25.45 M) with loss before overhead, payroll, taxes, and interest of (5.45 M).
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Biocept. Please refer to our Terms of Use for any information regarding our disclosure principles.